From: Analysis of trends and prospects regarding stents for human blood vessels
Polymer | Tg (°C) | Tm (°C) | Modulus (GPa) | Strength (MPa) | Elongation at break (%) | Degradation (months) |
---|---|---|---|---|---|---|
PLA | 60 | 180–190 | 2–4 | 65 | 2–6 | 18–30 |
PDLLA | 55 | Amorph. | 1–3.5 | 40 | 1–2 | 3–4 |
PLLA | 60–65 | 175 | 2–4 | 60–70 | 2–6 | > 24 |
PDLGA (50/50) | 45 | Amorph. | 1–4.3 | 45 | 1–4 | 1–2 |
PLGA (82/12) | 50 | 135–145 | 3.3–3.5 | 65 | 2–6 | 12–18 |
PCL | − 54 | 55–60 | 0.34–0.36 | 23 | > 4000 | 24–36 |
PLA/PCL (70/30) | 20 | 100–125 | 0.02–0.04 | 2–4.5 | > 100 | 12–24 |
WE43 (Mg alloy) | N.A | 540–640 | 40–50 | 220–330 | 2–20 | ~ 12 |
SS 316 L | N.A | 1371–1399 | 193 | 668 | 40 | Biostable |
CoCr | N.A | ~ 1454 | 210–235 | > 1000 | 40 | Biostable |